A prospective study on targeted therapies of non-small cell lung cancer using almonertinib or anlotinib
Objective:To study the therapeutic effect of targeted therapies with almonertinib or anlotinib on non-small cell lung cancer(NSCLC).Methods:A total of 92 patients with NSCLC treated in our hospital from January 2020 to June 2023 were selected as the study subjects,and randomly divided into the almonertinib group and the anlotinib group,with 46 patients in each group.The almonertinib group was treated with almonertinib,while the anlotinib group was treated with anlotinib.The immune indicators,levels of inflammatory factors,therapeutic effect,and incidence of adverse reactions were compared between the two groups.Results:After treatment,the levels of mature T lymphocytes and natural killer cells in the almonertinib group were higher than those in the anlotinib group(P<0.05).The levels of high-sensitivity C-reactive protein,interleukin-6 and interleukin-8 in the almonertinib group were lower than those in the anlotinib group(P<0.05).Conclusion:Almonertinib is more effective than anlotinib in the treatment of NSCLC.It can improve the levels of immune indicators and inflammatory factors.
Non-small cell lung cancerAlmonertinibAnlotinibControlled study
NETL
NSTL
万方数据
维普
